Talha Badar/X
May 18, 2025, 11:13
Talha Badar: Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress
Talha Badar, Hematology/Oncology specialist at Mayo Clinic, posted on X:
“Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress, New England Journal of Medicine.
With use of potent BCR: ABL1 directed TKI, long term survival outcome has significantly improved (>75%).
Important question from clinical standpoint : Is chemo-free (blinatumomab) induction with TKI is better than vs chemo +TKI?
Hopefully will be answered by EA9181 study: Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults.”
More posts featuring Talha Badar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 7, 2025, 17:41
Jun 7, 2025, 16:47
Jun 7, 2025, 16:40
Jun 7, 2025, 16:30
Jun 7, 2025, 16:07
Jun 7, 2025, 15:49